Drug Development.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

Drug Development.

Background: Glucagon-like peptide 1 (GLP-1) is a peptide hormone that plays several physiological roles in treating diabetes and in protecting the brain. Recent clinical trials testing 4 different GLP-1 class drugs in phase 2 trials showed a clear correlation between neuroprotection and the ability to cross the BBB. Exenatide and Lixisenatide both showed excellent protective effects in patients Parkinson's disease (PD) and both drugs can readily cross the BBB.

Drug Development.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

Drug Development.

Background: Individuals with type 2 diabetes mellitus (T2DM) face an increased risk of dementia. Recent discoveries indicate that SGLT2 inhibitors, a newer class of anti-diabetic medication, exhibit beneficial metabolic effects beyond glucose control, offering a potential avenue for mitigating the risk of Alzheimer's disease (AD). However, limited evidence exists regarding whether the use of SGLT2 inhibitors effectively reduces the risk of AD.

Drug Development.

Background: Effective early intervention of mild cognitive impairment (MCI) is the key for preventing dementia. However, there is currently no drug for MCI. As a multi-targeted neuroprotective agent, butylphthalide has been demonstrated to repair cognition in patients with vascular cognitive impairment, and has the potential to treat MCI due to Alzheimer's disease (AD).

Drug Development.

Background: Cerebral small vessel disease (CSVD) is one of the most common nervous system diseases. Hypertension and neuroinflammation are considered important risk factors for the development of CSVD and white matter (WM) lesions.

Method: We used the spontaneously hypertensive rat (SHR) as a model of early-onset CSVD and administered epimedium flavonoids (EF) for three months.

Correction: Camptothecin-based prodrug nanomedicines for cancer therapy.

Correction for 'Camptothecin-based prodrug nanomedicines for cancer therapy' by Renshuai Zhang , , 2023, , 17658-17697, https://doi.org/10.1039/D3NR04147F.

Drug Development.

Background: Cognitive impairment, a common aging-related pathology, is a risk factor for dementia. Echinacoside (ECH), derived from the traditional Chinese medicine Cistanche deserticola, shows anti-aging properties including anti-inflammation, oxidative stress reduction, and neuronal protection. Despite its benefits, the beneficial impact of ECH on age-related cognitive decline remains unclear.

Drug Development.

Alzheimer's Disease (AD) is characterized by the amyloid plaques in patient brain. The plaques are formed by β-amyloid peptides (Aβs) that derive from the cleavage by γ-secretase. Over 300 AD pathogenic mutations have been identified in presenilin1/2 (PS1/PS2), the catalytic subunit of γ-secretase.

Drug Development.

Background: ABCA1-mediated cholesterol transport is a central feature in many lipid- dependent diseases including APOE4-associated Alzheimer's disease and atherosclerosis-CVD. ABCA1 upregulation of RNA transcription by nuclear factors (LXR, RXR) have been associated with liver side-effects because of the common promotor element for ABCA1 and Fatty Acid Synthase. The ABCA1 agonist CS6253, derived from the C-terminal of apoE was designed to stabilize and enhance ABCA1 function, thereby providing a safe alternative to transcriptional upregulation.

Dementia Care Research and Psychosocial Factors.

Background: Cognitive training and exercise intervention are suggested for enhancing cognitive functions in people with mild cognitive impairment (MCI). The use of virtual reality (VR) has been applied in cognitive training and exercise intervention in recent decades. However, it is still unclear whether VR-based intervention is a useful means to enhance cognitive functions in people with MCI.

Dementia Care Research and Psychosocial Factors.

Background: Dementia is strongly linked to increased care use, but the use of formal and informal care throughout dementia journey remains unclear.

Method: Within a population-based cohort study, we identified 240 older adults (aged ≥78 years) with who developed CIND and 155 with incident dementia. These participants were matched to 480 and 310 cognitively intact participants, respectively, and their formal and informal care use and care hours were compared with a control groups before and after diagnosis of cognitive disorders.

Dementia Care Research and Psychosocial Factors.

Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.

Dementia Care Research and Psychosocial Factors.

Background: To systematically analyze the current situation and application of caregiver empowerment assessment tools at home and abroad, to provide a reference for the future development of caregiver empowerment assessment tools and the assessment of caregiver empowerment level.

Method: According to the research method of scope review, the relevant literature from the establishment of the database to October 2023 was searched, and the references of the included literature were traced, and the relevant literature of the caregiver empowerment assessment tool was comprehensively collected.

Result: A total of 856 articles were retrieved.

Dementia Care Research and Psychosocial Factors.

Background: To understand the current situation of the care burden of elderly caregivers in the community and explore the influencing factors.

Method: 100 family caregivers in community were assessed using the General information questionnaire and Home Caregiver Burden Scale (CBI) in Ningbo City In China.

Results: The care burden's average scores of 100 family caregivers in community was 52.

Dementia Care Research and Psychosocial Factors.

Background: Data from high-income countries (HICs) suggest a decline in age-specific incidence rates of dementia. However, this has happened primarily in HICs, with low- and middle- income countries (LMICs) facing two main challenges: a higher burden of risk factors and, in general, a faster ageing population. Most people with dementia live in LMICs, and this is set to increase, thus requiring urgent and robust action to prevent, treat and support people with dementia and their families.

Exploring Compassion Fatigue in Pediatric Nursing: A Cross-Sectional Study.

Background: Compassion fatigue is a state of emotional and physical exhaustion that arises from frequent contact with people who have experienced trauma or stress, which may affect particularly those working in health care. This study aimed to elucidate the prevalence and determinants of compassion fatigue among pediatric nurses.

Methods: A survey was administered to pediatric nurses at a tertiary hospital in Jiangsu province, China.

Dementia Care Research and Psychosocial Factors.

Background: This prediction model quantifies the risk of cognitive impairment. This aim of this study was to develop and validate a prediction model to calculate the 6-year risk of cognitive impairment.

Methods: Participants from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) 2008-2014 and 2011-2018 surveys were included for developing the cognitive impairment prediction model.

Dementia Care Research and Psychosocial Factors.

Background: Our authors from around the world met to summarise the available knowledge, decide which potentially modifiable risk factors for dementia have compelling evidence and create the most comprehensive analysis to date for potentially modifiable risk factors to inform policy, give individuals the opportunity to control their risks and generate research.

Method: We incorporated all risk factors for which we judged there was strong enough evidence. We used the largest recent worldwide meta-analyses for risk factor prevalence and relative risk and if not available the best data.

Dementia Care Research and Psychosocial Factors.

Background: While symptomatic treatment for Alzheimer's disease has been available for three decades disease modifying treatment does not exist. New drug treatments, known as immunotherapies, which remove amyloid from the brain offer hope, but the clinical significance remains uncertain.

Method: Systematic reviews of the literature, expert consensus, and information from clinical environments.

Dementia Care Research and Psychosocial Factors.

Background: The 2020 Lancet Commission on dementia prevention, intervention and care estimated that up to 40% of dementia cases could be prevented by tackling 12 potentially modifiable risk factors, namely less education, hearing loss, hypertension, physical inactivity, diabetes, social isolation, excessive alcohol consumption, air pollution, smoking, obesity, traumatic brain injury, depression. As more evidence on risk factors emerges, the Lancet standing commission on dementia met to update evidence on established dementia risk factors and to consider the evidence for other risk factors.

Method: We used a lifecourse approach to understand how to reduce risk or prevent dementia, as many risks operate at different timepoints in the lifespan.

Dementia Care Research and Psychosocial Factors.

Background: Older adults with cognitive impairments will benefit from multicomponent interventions include cognitive training, exercise, and lifestyle modifications. Many digital therapeutic products predominantly focus on computerized cognitive training, lacking effective approaches to other crucial interventions. This study aimed to investigate the long term effects of multidimensional comprehensive cognitive intervention training program - Brain and Body Rehab Training (BBRT), which integrates multidomain cognitive training with physical-cognitive training and multidimensional lifestyle interventions on cognitive performance in participants with cognitive impairment after a 8-month follow-up.

Dementia Care Research and Psychosocial Factors.

Background: In the context of heightened attention to dementia, research gaps persist in the seamless integration of clinical and non-clinical care, including long-term support. This study aims to examine potential gaps in social support for US adults with cognitive impairment, focusing on the transition before and after a dementia diagnosis.

Methods: In this ambidirectional cohort study, we examined data from the Health and Retirement Survey(HRS) for US adults over 50, using data from 2000 to 2018.

Dementia Care Research and Psychosocial Factors.

Background: Recognizing perceived stress as a modifiable cognitive risk factor, mindfulness-based programs emerge as promising for stress mitigation in older adults with Mild cognitive impairment (MCI). However, existing research, primarily observational and focused on chronic patients and caregivers, necessitates developing and evaluating MCI-specific mindfulness interventions.

Design: A two-arm and assessor-blinded randomized controlled trial.

Dementia Care Research and Psychosocial Factors.

Background: Worldwide, ∽40% of dementia cases are preventable by interventions to target major modifiable risk factors. In the multimodal interventions to delay dementia and disability in rural China (MIND-China), we aim to test the effect of multimodal intervention programs on maintaining cognitive and physical function among rural-dwelling older adults and discuss about challenges and opportunities for a multidomain intervention study in a rural population.

Method: MIND-China targets people who are aged 60-79 years and living in rural communities (52 villages) in Shandong.